Inve India ▾

Rubicon Research share price & results

Rubicon Research Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

US-focused specialty pharma making complex generics, nasal-spray drug-devices and branded CNS drugs.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue534 ₹ crore+51.7% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin24.0 %+2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit85.0 ₹ crore+97.7% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity31.58 %−1.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-1.37 %−8.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)46.78 %−13.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 1 judged target kept · 9 open · verdicts reflect calls analysed to Q1 FY27.

Rubicon Research Limited management guidance track record on Inve: 10 targets tracked across analysed earnings calls (1 achieved, 0 missed, 9 open).

TargetOriginal wordingSaidLatest callVerdict
R&D Productivity Multiplierupward of 5x
Call transcript, Q3 FY26 · 3 Feb 2026		Q3 FY26Q1 FY27:Stands at 5.5x, which meets the 'upward of 5x' target.
Call transcript, Q1 FY27 · 14 Aug 2026		Achieved
EBITDA MarginSustain at current levels (~22.9%)
Call transcript, Q2 FY26 · 13 Nov 2025		Q2 FY26Q1 FY27:Achieved 24.2% margin in Q1. Management revised full-year FY27 guidance upwards from the previous 22-23% range.
Call transcript, Q1 FY27 · 14 Aug 2026		Revised Up
R&D Spend as % of Revenue10-11% over 5 years
Call transcript, Q2 FY26 · 13 Nov 2025		Q2 FY26Q1 FY27:10.9% for the quarter, remaining within the long-term target range.
Call transcript, Q1 FY27 · 14 Aug 2026		On Track

Source: Inve Guidance Tracker for Rubicon Research Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

9 of Rubicon Research Limited's 10 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 7 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,509.6 +1.30% · +₹19.3

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +161.5% 1Y

₹0.5k₹1.0k₹1.5kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 13 Nov 2025Q3 FY26 — 3 Feb 2026Q4 FY26 — 29 May 2026Q1 FY27 — 14 Aug 2026

1Y: ₹577.25 on 24 Oct 2025 → ₹1,509.6. High ₹1,860.6 (8 Sept 2026), low ₹577.25 (24 Oct 2025).

Previous close
₹1,490.3
Market cap
₹24.9k Cr
52-week range
₹589.85 – ₹1,860.6
One year
+155.93%
Price to earnings (TTM to Jun 2026)
86.20×
Return on equity (TTM to Jun 2026)
31.58%

Overview

Symbol
NSE:RUBICON
Exchange
NSE
Currency
INR

What Rubicon Research Limited does

Based on the company's own presentations, annual report and earnings calls.

Rubicon Research is an R&D-driven formulations, manufacturing and marketing company built around complex generics, drug-device combinations (including nasal sprays) and branded specialty products sold mainly into the US regulated market. It began in 1999 as a contract development organisation and has progressively moved up the value chain to its own ANDA filings, its own US front-end, and, since 2024, branded specialty launches through its US subsidiary Validus Pharmaceuticals. Manufacturing is carried out across its own cGMP sites in India (Ambernath and Satara, plus the newly acquired Pithampur plant) alongside outsourced third-party capacity, supported by USFDA-inspected R&D centres in India and Canada. In FY26 it also acquired an 85% stake in Arinna Lifesciences to build a branded CNS/chronic-disease business in the Indian market.

Segments

  • Specialty Products
  • Generics (ANDA-based)
  • Validus Pharmaceuticals (US branded platform)
  • Arinna Lifesciences (India CNS)
Approved products (ANDAs + NDAs)
84 total approved (76 ANDAs, 8 NDAs) as of Mar 2026
Products under USFDA review
24 (as of Mar 2026)
Manufacturing sites
3 sites (Ambernath, Satara, Pithampur) making oral solids, oral liquids, ointments and drug-device nasal spray products
USFDA-inspected R&D facilities
2, located in India and Canada
US states licensed to market (Validus)
43 states
Ambernath manufacturing site
14,000 sq. m cGMP facility; one of the largest single-site nasal spray manufacturing capacities in the world
Founded 1999Headquarters Thane, Maharashtra, India Company website

How the price took the results

close before → close after

Q1 FY27
−0.1%
14 Aug
Q4 FY26
+3.9%
29 May
Q3 FY26
+4.8%
3 Feb
Q2 FY26
+4.3%
13 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Rubicon Research Limited

Free account: one company. Everything above stays public.

Write why you follow Rubicon Research Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Rubicon Research Limited

Guides on how to read this kind of business and the numbers that matter.